We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.

Delisted

RVNC was delisted on the 5th of February, 2025.

81 hedge funds and large institutions have $540M invested in Revance Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

55% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 20

17% more capital invested

Capital invested by funds: $463M → $540M (+$77M)

9% more funds holding

Funds holding: 7481 (+7)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
81
Holders Change
+7
Holders Change %
+9.46%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
14
Increased
31
Reduced
20
Closed
6
Calls
$364K
Puts
Net Calls
+$364K
Net Calls Change
+$526K

RVNC Hedge Fund Activity: Q4 2016 in Review

81 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2016, worth a combined $540M — up 17% from $463M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new RVNC positions and 6 closed out — a net gain of 8 holders — while 31 added to existing stakes and 20 trimmed.

The largest buyer was ArrowMark Colorado Holdings, adding an estimated $3.27M. The largest seller was Wellington Management Group, cutting an estimated $4.42M.

  • 81 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2016, up from 74 in Q3 2016.
  • Funds reported $540M of Revance Therapeutics, Inc. stock for Q4 2016, up 17% quarter-over-quarter.
  • 14 funds opened new Revance Therapeutics, Inc. positions in Q4 2016 and 6 closed out, a net change of +8 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q4 2016 was ArrowMark Colorado Holdings, an estimated $3.27M added.
  • The largest Revance Therapeutics, Inc. seller in Q4 2016 was Wellington Management Group, an estimated $4.42M sold.

Based on aggregated 13F filings for Q4 2016.